Drug-drug similarities play a very important role in modern medicine, chemistry, and biology. Having in-depth knowledge of the therapeutic structures of drugs aids wet laboratory work and can greatly improve drug research and development efficiency. Many computational methods have been developed for the analysis of such drug similarities. One of the diseases studied for treatment in this area is the Ebola virus. The Ebola virus is a deadly pathogen. Although many researchers around the world have made various efforts on this deadly pathogen, the mortality rate is quite high. Computational approaches are considered to be very useful for antiviral drug discovery. Developing specific antiviral drugs is expensive and takes a long time. By providing an opportunity for the rapid deployment of effective therapeutics, reusing FDA-approved drugs could provide treatments with known preclinical, pharmacokinetic, pharmacodynamic, and toxicity profiles that can enter clinical trials rapidly. The approach in this study is the idea that the combination of drugs may be more effective for the treatment of Ebola due to their similarities and similarities of drugs approved for Ebola, unlike previous studies. For this reason, similarity analyzes of drugs approved for the treatment of the Ebola virus or investigated in clinical studies were performed with the Atom Pair fingerprint algorithm. Then, molecule and infrastructure molecular scaffolds of the drugs selected according to this similar result were created with Scaffold Network Graph (SNG) algorithms and drug structures were analyzed. Public databases (PubChem, DrugBank) and drugs published in the literature for the treatment of Ebola were used for analysis. The molecular, molecular infrastructure and core structures of the drugs that show the most similarity to the FDA approved drugs, which were analyzed with the Scaffold Network Graph algorithm, are shown graphically. When these results were evaluated, it was seen that a combination of Favipiravir, which has also been used in previous outbreaks, and Molnupiravir, which is currently the first approved oral drug candidate for COVID-19, could be effective in the treatment of Ebola. We also think that knowing the chemical structure similarities of drugs currently used to develop other drugs or drug combinations, their inhibitors, and the core structure or structures in drug molecules that are effective against the Ebola virus will be beneficial for chemists.